品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | N125272-5mg | 5mg | 现货 | 1315355-93-1 |
NG25,TGF-β活化激酶(TAK1)抑制剂 NG25 |
Moligand™, ≥98% |
|
|
阿拉丁 | N125272-10mg | 10mg | 现货 | 1315355-93-1 |
NG25,TGF-β活化激酶(TAK1)抑制剂 NG25 |
Moligand™, ≥98% |
|
|
阿拉丁 | N125272-100mg | 100mg | 现货 | 1315355-93-1 |
NG25,TGF-β活化激酶(TAK1)抑制剂 NG25 |
Moligand™, ≥98% |
|
|
阿拉丁 | N125272-25mg | 25mg | 现货 | 1315355-93-1 |
NG25,TGF-β活化激酶(TAK1)抑制剂 NG25 |
Moligand™, ≥98% |
|
|
阿拉丁 | N421221-1ml | 1ml | 现货 | 1315355-93-1 |
NG25 NG25 |
Moligand™, 10mM in DMSO |
|
|
麦克林 | N883274-1mg | 1mg | 订前询问 | 1315355-93-1 |
NG25 NG25 |
≥99% |
|
|
麦克林 | N883274-5mg | 5mg | 订前询问 | 1315355-93-1 |
NG25 NG25 |
≥99% |
|
|
罗恩 | R021187-10mg | 10mg | 5~7个工作日 | 1315355-93-1 |
N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲... N-[4-[(4-ethylpiperazin-1-yl... |
98% |
|
|
罗恩 | R021187-5mg | 5mg | 5~7个工作日 | 1315355-93-1 |
N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲... N-[4-[(4-ethylpiperazin-1-yl... |
98% |
|
|
MARY | MR132298-10mg | 10mg | 订前咨询 | 1315355-93-1 |
N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲... N-[4-[(4-ethylpiperazin-1-yl... |
98% |
|
|
MARY | MR132298-5mg | 5mg | 订前咨询 | 1315355-93-1 |
N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲... N-[4-[(4-ethylpiperazin-1-yl... |
98% |
|
|
源叶 | S82820-1mg | 1mg | 现货 | 1315355-93-1 |
NG25 NG25 |
98% |
|
|
源叶 | S82820-5mg | 5mg | 现货 | 1315355-93-1 |
NG25 NG25 |
98% |
|
|
源叶 | S82820-10mg | 10mg | 现货 | 1315355-93-1 |
NG25 NG25 |
98% |
|
|
源叶 | T95601-1ml | 1ml | 期货,请咨询 | 1315355-93-1 |
NG25 NG25 |
10mM in DMSO |
|
|
毕得 | BD295331-10mg | 10mg | 现货 | 1315355-93-1 |
3-((1H-吡咯并[2,3-b]吡啶-4-基)氧基)-... 3-((1H-Pyrrolo[2,3-b]pyridin... |
98% |
|
|
毕得 | BD295331-50mg | 50mg | 现货 | 1315355-93-1 |
3-((1H-吡咯并[2,3-b]吡啶-4-基)氧基)-... 3-((1H-Pyrrolo[2,3-b]pyridin... |
98% |
|
|
毕得 | BD295331-25mg | 25mg | 现货 | 1315355-93-1 |
3-((1H-吡咯并[2,3-b]吡啶-4-基)氧基)-... 3-((1H-Pyrrolo[2,3-b]pyridin... |
98% |
|
|
毕得 | BD295331-100mg | 100mg | 现货 | 1315355-93-1 |
3-((1H-吡咯并[2,3-b]吡啶-4-基)氧基)-... 3-((1H-Pyrrolo[2,3-b]pyridin... |
98% |
|
|